HOMA-IR 2.5 — the insulin-resistance number your doctor probably skipped
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a simple calculated index derived from fasting glucose and fasting insulin: (fasting glucose mmol/L × fasting insulin µIU/mL) / 22.5. A HOMA-IR of 2.5 sits at the threshold most metabolic research uses for early insulin resistance — values below ~1.5 are typically considered insulin-sensitive, 1.5–2.5 borderline, and ≥2.5 indicative of meaningful insulin resistance. Crucially, HOMA-IR can rise years before HbA1c moves out of normal range, making it a much earlier warning signal for the metabolic-syndrome trajectory than a routine GP panel typically captures.
Reference ranges
| Insulin-sensitive | < 1.5 |
| Borderline | 1.5 – 2.5 |
| Insulin resistant | 2.5 – 5.0 |
| Severely insulin resistant | > 5.0 |
What this marker measures
HOMA-IR estimates insulin resistance from a single fasting blood draw. The underlying physiology: in healthy people, fasting insulin is low (typically <8 µIU/mL) because tissues are sensitive to it. As tissues become resistant, the pancreas compensates by secreting more insulin to keep glucose in range — fasting insulin rises while fasting glucose stays normal. HOMA-IR multiplies the two and so captures this compensation phase before glucose itself drifts up. The classic HOMA-IR validation study against gold-standard euglycaemic clamps showed correlation of 0.85+ across populations.
Why might it be elevated?
- ·Visceral adiposity (waist circumference is a strong predictor)
- ·Sedentary lifestyle — exercise sensitises muscle to insulin within days
- ·Diet pattern: high refined carbohydrate, low fibre
- ·Sleep deprivation — even one week of restricted sleep raises HOMA-IR
- ·Cortisol elevation (chronic stress, glucocorticoid medication)
- ·PCOS in women
- ·Genetic predisposition — family history of type 2 diabetes
Why might it be low?
- ·Athletic training, particularly resistance training
- ·Caloric restriction or fasting
- ·Pharmacological insulin sensitisation (metformin, GLP-1 agonists)
- ·Hyperthyroidism (rare — usually transient)
FAQ
Is HOMA-IR 2.5 prediabetic?+
Not by formal HbA1c criteria, but research literature consistently shows HOMA-IR rising years before HbA1c reaches the 5.7% prediabetic threshold. A reading of 2.5 indicates compensated insulin resistance — tissues are less responsive but the pancreas is still keeping glucose normal.
How do I lower it?+
The most reliable lifestyle interventions in randomised trials: reducing visceral adiposity (5–10% body weight loss), adding resistance training, prioritising sleep, and reducing refined-carbohydrate intake. Pharmacological options exist but are typically gated behind a formal diabetes or PCOS diagnosis.
How often should I retest?+
Every 3–6 months if you're actively intervening. Same time of day, fasted (12+ hours), no exercise the day before — fasting insulin is sensitive to all of these.
This page describes biomarker research and reference ranges for self-tracking and research-context discussion only. It is not medical advice, not a diagnosis, and not a substitute for a qualified physician. Take any concerns about your health to a clinician.
Have your own panel? Read it next to the standard reference ranges with our free analyse tool.
Analyse my blood work →- BiomarkerHbA1c 5.7%
HbA1c at 5.7% is the formal threshold the ADA uses to define prediabetes — meaning your average blood glucose has been elevated over the past 2–3 months. What the number means and the research literature on intervention.
- BiomarkerFasting glucose 100
Fasting glucose at 100 mg/dL (5.6 mmol/L) sits exactly at the ADA threshold for impaired fasting glucose. What it indicates, why it precedes HbA1c shifts, and the research-literature interpretation.
- BiomarkerFasting insulin 12
Fasting insulin of 12 µIU/mL is above the optimal threshold most metabolic research uses (~8). What it indicates, why doctors miss it, and the research literature on early insulin resistance.
- ResearchRetatrutide 40 mg pen
Retatrutide is a triple agonist at the GLP-1, GIP, and glucagon receptors. The 40 mg pen is the highest-dose presentation in the Omega Grade catalogue
- ResearchCagrilintide 10 mg
Cagrilintide is a long-acting amylin analogue most widely investigated in combination with semaglutide under the CagriSema programme. Commonly stacked
- ResearchRetatrutide 30 mg kit
Retatrutide 30 mg lyophilised vial kit — the mid-dose research presentation. Includes bacteriostatic water, syringes, and swabs.